Acute myeloid leukemia and myelodysplastic syndromes related to radiation

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) related to radiation are therapy-related or exposure-related hematologic malignancies that develop as a consequence of prior exposure to ionizing radiation. This condition is classified under therapy-related myeloid neoplasms and is recognized by Orphanet under code 164726 (ICD-10: D46.7). These disorders arise when radiation damages the DNA of hematopoietic stem cells in the bone marrow, leading to genomic instability, abnormal blood cell production, and eventual malignant transformation. The latency period between radiation exposure and disease onset is typically 2 to 10 years, though it can vary depending on the dose and type of radiation received. The disease primarily affects the hematopoietic (blood-forming) system. In MDS, the bone marrow produces abnormal and ineffective blood cells, leading to cytopenias — low red blood cells (anemia), low white blood cells (leukopenia), and low platelets (thrombocytopenia). Patients may experience fatigue, recurrent infections, easy bruising, and bleeding. MDS related to radiation frequently progresses to AML, a rapidly progressing cancer of the blood and bone marrow characterized by the accumulation of immature myeloid blast cells. Radiation-related AML often involves complex cytogenetic abnormalities, including deletions of chromosomes 5 and 7, which are associated with a poor prognosis. Treatment options are generally similar to those for de novo AML and MDS but outcomes tend to be less favorable. Management may include supportive care (transfusions, growth factors, antibiotics), hypomethylating agents such as azacitidine or decitabine, intensive chemotherapy, and allogeneic hematopoietic stem cell transplantation, which remains the only potentially curative approach. However, therapy-related myeloid neoplasms, including those caused by radiation, are generally associated with poorer response rates to standard chemotherapy and lower overall survival compared to primary AML or MDS. Clinical trials exploring novel targeted therapies and combination regimens are ongoing.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Acute myeloid leukemia and myelodysplastic syndromes related to radiation